Agreement of Amyloid PET and CSF Biomarkers for Alzheimer's Disease on Lumipulse

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2019 Aug 30

PMID 31464088

Citations 82

Authors

Daniel Alcolea

Jordi Pegueroles

Laia Munoz

Valle Camacho

Diego Lopez-Mora

Alejandro Fernandez-Leon

Nathalie Le Bastard

Els Huyck

Alicia Nadal

Veronica Olmedo

Frederic Sampedro

Victor Montal

Eduard Vilaplana

Jordi Clarimon

Rafael Blesa

Juan Fortea

Alberto Lleo

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the cutoffs that optimized the agreement between F-Florbetapir positron emission tomography (PET) and Aβ1-42, Aβ1-40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available F-Florbetapir imaging.

Methods: Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of Aβ1-42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with F-Florbetapir PET and evaluated concordance between markers of the amyloid category.

Results: Aβ1-42, tTau and pTau (but not Aβ1-40) and the ratios with Aβ1-42 had good diagnostic agreement with F-Florbetapir PET. As a marker of amyloid pathology, the Aβ1-42/Aβ1-40 ratio had higher agreement and better correlation with amyloid PET than Aβ1-42 alone.

Interpretation: CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of Aβ1-42 with Aβ1-40 increases the agreement between markers of amyloid pathology.

Citing Articles

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.

Leuzy A, Bollack A, Pellegrino D, Teunissen C, La Joie R, Rabinovici G Alzheimers Dement. 2025; 21(3):e14528.

PMID: 40042435 PMC: 11881640. DOI: 10.1002/alz.14528.

A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic.

Anastasi F, Fernandez-Lebrero A, Ashton N, Ortiz-Romero P, Torres-Torronteras J, Gonzalez-Escalante A Alzheimers Dement. 2025; 21(2):e14609.

PMID: 39998475 PMC: 11852974. DOI: 10.1002/alz.14609.

Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers.

Gonzalez A, Goossens J, Campuzano E, Sala I, Sanchez-Saudinos M, Rodriguez-Baz I Alzheimers Res Ther. 2025; 17(1):51.

PMID: 39994784 PMC: 11849174. DOI: 10.1186/s13195-025-01685-y.

The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.

Arslan B, Brum W, Pola I, Therriault J, Rahmouni N, Stevenson J Alzheimers Res Ther. 2025; 17(1):48.

PMID: 39972340 PMC: 11837363. DOI: 10.1186/s13195-025-01692-z.

Plasma Biomarkers in the Distinction of Alzheimer's Disease and Frontotemporal Dementia.

Gomez-Tortosa E, Aguero-Rabes P, Ruiz-Gonzalez A, Wagner-Reguero S, Tellez R, Mahillo I Int J Mol Sci. 2025; 26(3).

PMID: 39940998 PMC: 11818795. DOI: 10.3390/ijms26031231.

References

Alcolea D, Carmona-Iragui M, Suarez-Calvet M, Sanchez-Saudinos M, Sala I, Anton-Aguirre S . Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis. 2014; 42(1):157-67. DOI: 10.3233/JAD-140240. View

Bartlett J, Frost C, Mattsson N, Skillback T, Blennow K, Zetterberg H . Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. Biomark Med. 2012; 6(4):391-400. DOI: 10.2217/bmm.12.49. View

Toombs J, Foiani M, Wellington H, Paterson R, Arber C, Heslegrave A . Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimers Dement (Amst). 2018; 10:311-321. PMC: 5956932. DOI: 10.1016/j.dadm.2018.02.005. View

Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O . CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016; 3(3):154-65. PMC: 4774260. DOI: 10.1002/acn3.274. View

Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H . Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem. 2007; 101(4):1053-9. DOI: 10.1111/j.1471-4159.2006.04404.x. View

Toledo J, Bjerke M, Da X, Landau S, Foster N, Jagust W . Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurol. 2015; 72(5):571-81. PMC: 5642905. DOI: 10.1001/jamaneurol.2014.4829. View

Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A . CSF Aβ - an excellent but complicated Alzheimer's biomarker - a route to standardisation. Clin Chim Acta. 2016; 467:27-33. DOI: 10.1016/j.cca.2016.05.014. View

Fagan A, Head D, Shah A, Marcus D, Mintun M, Morris J . Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009; 65(2):176-83. PMC: 2763631. DOI: 10.1002/ana.21559. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

10.

Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K . Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurol. 2017; 74(12):1492-1501. PMC: 5822196. DOI: 10.1001/jamaneurol.2017.2814. View

11.

Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche J . Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther. 2015; 7(1):30. PMC: 4450486. DOI: 10.1186/s13195-015-0114-5. View

12.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski J, Bittner T . CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018; 14(11):1470-1481. PMC: 6119541. DOI: 10.1016/j.jalz.2018.01.010. View

13.

Rieck J, Rodrigue K, Kennedy K, Devous Sr M, Park D . The effect of beta-amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signal. Hum Brain Mapp. 2015; 36(7):2514-26. PMC: 4617762. DOI: 10.1002/hbm.22788. View

14.

Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R . Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis. 2010; 2010. PMC: 2925386. DOI: 10.4061/2010/986310. View

15.

Lleo A, Irwin D, Illan-Gala I, McMillan C, Wolk D, Lee E . A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurol. 2018; 75(6):738-745. PMC: 5885205. DOI: 10.1001/jamaneurol.2018.0118. View

16.

Delaby C, Munoz L, Torres S, Nadal A, Le Bastard N, Lehmann S . Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Clin Chim Acta. 2018; 490:98-101. DOI: 10.1016/j.cca.2018.12.021. View

17.

Illan-Gala I, Pegueroles J, Montal V, Vilaplana E, Carmona-Iragui M, Alcolea D . Challenges associated with biomarker-based classification systems for Alzheimer's disease. Alzheimers Dement (Amst). 2018; 10:346-357. PMC: 6114028. DOI: 10.1016/j.dadm.2018.03.004. View

18.

Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernandez S, Videla L . Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. Alzheimers Dement. 2017; 13(11):1251-1260. PMC: 5660938. DOI: 10.1016/j.jalz.2017.03.007. View

19.

Landau S, Mintun M, Joshi A, Koeppe R, Petersen R, Aisen P . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012; 72(4):578-86. PMC: 3786871. DOI: 10.1002/ana.23650. View

20.

Schindler S, Gray J, Gordon B, Xiong C, Batrla-Utermann R, Quan M . Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement. 2018; 14(11):1460-1469. PMC: 6119652. DOI: 10.1016/j.jalz.2018.01.013. View